Chapter 1. Discovery and Development of Sunitinib (SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and Angiogenesis
- Rongshi Li,
- Jeffrey A. Stafford
Published Online: 28 SEP 2009
DOI: 10.1002/9780470524961.ch1
Copyright © 2009 John Wiley & Sons, Inc.
Book Title
Kinase Inhibitor Drugs
Additional Information
How to Cite
Sun, C. L., Christensen, J. G. and McMahon, G. (2009) Discovery and Development of Sunitinib (SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and Angiogenesis, in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch1
Editor Information
Takeda San Diego, Inc., San Diego, CA 92121, USA
Publication History
- Published Online: 28 SEP 2009
- Published Print: 2 OCT 2009
ISBN Information
Print ISBN: 9780470278291
Online ISBN: 9780470524961
- Summary
- Chapter
- References
Keywords:
- multitarget tyrosine kinase inhibitor of tumor growth, survival, and angiogenesis;
- Sunitinib (SU11248, Sutent™; Pfizer Inc) - oral, multitargeted tyrosine kinase inhibitor of VEGF receptors;
- SU 11248 in vitro protein kinase target profile
Summary
This chapter contains sections titled:
Sunitinib
Receptor Tyrosine Kinase Signaling Affects Multiple and Diverse Cancer Processes
Role of Receptor Tyrosine Kinases in Pathologic Tumor Angiogenesis
SU 5416: Discovery of First-Generation VEGFR RTK Inhibitors
SU 6668: Inhibitor of PDGFR and VEGFR Tyrosine Kinases
Design, Discovery, and Development Rationale for SU 11248
SU 11248 in vitro Protein Kinase Target Profile
Simultaneous Inhibition of VEGFR, PDGFR, and KIT (SCFR) RTKs Established a Unique Mechanism of Action for SU 11248
SU 11248 PKPD Studies Established the Optimal Dosing Parameters
SU 11248 Nonclinical Studies Supported Clinical Strategy and Tumor Indication Selection
SU 11248: Translational Studies Provided a Drug Registration Path
Summary
Acknowledgments
References